AFP and neoplasm: It is due to a heterozygous deletion on chromosome 19 that encodes a functional chimeric protein (DNAJB1-PRKACA) and characterized by being less aggressive with a normal alpha-fetoprotein (AFP) tumour marker and a female predominance [5, 6].